Zunsemetinib clinical trials
Also written ATI-450 and CDD-450.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses zunsemetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Aclaris Therapeutics, Inc. (5) · University of Kansas Medical Center (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses zunsemetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)CompletedPhase 2Aclaris Therapeutics, Inc.NCT05279417Written as ATI-450 50 mg oral tablet BID
- ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedPhase 2Aclaris Therapeutics, Inc.NCT05216224Written as ATI-450
- A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)CompletedPhase 2University of Kansas Medical CenterNCT04481685Written as ATI-450
- Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisTerminatedPhase 2Aclaris Therapeutics, Inc.NCT05511519Written as ATI-450
- Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)TerminatedPhase 2Aclaris Therapeutics, Inc.NCT04524858Written as ATI-450
- Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RACompletedPhase 2Aclaris Therapeutics, Inc.NCT04247815Written as ATI-450
Given beside what is tested · 2 — zunsemetinib is usual care or a partner of the new treatment
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisRecruitingPhase 1/2Washington University School of MedicineNCT06374459Written as Zumsemetinib
- MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 1Washington University School of MedicineNCT06648434Written as Zunsemetinib
Codes
What other systems call zunsemetinib · ClinicalTrials.gg INT016039
- UNII (FDA) AX2VWG0ZCRZUNSEMETINIBOne source FDA
- NCI Thesaurus C182621ZunsemetinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AX2VWG0ZCR | ZUNSEMETINIB | One source FDA |
| NCI Thesaurus | C182621 | Zunsemetinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.